Chris Ryan

Epcoritamab-based treatment yielded durable remissions in patients with follicular lymphoma, both as first-line induction and maintenance.

The FDA approved T-DXd plus pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

The FDA has given a national priority voucher to teclistamab plus daratumumab for relapsed/refractory multiple myeloma, based on MajesTEC-3 data.

Varegacestat improved progression-free survival vs placebo in patients with progressing desmoid tumors.

Neoadjuvant niraparib plus dostarlimab led to pathologic complete responses in BRCA- or PALB2-mutated triple-negative breast cancer.

The FDA has approved niraparib and abiraterone acetate with prednisone for BRCA2-mutated mCSPC.

The EMA recommended conditional marketing authorization for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive NMIBC with CIS.

Circulating tumor DNA could represent a minimally invasive approach for detecting AKT pathway alterations in hormone receptor–positive breast cancer.

The FDA granted orphan drug designation to the B7-H3–targeted antibody-drug conjugate GSK’227 for small cell lung cancer.

T-DXd yielded iDFS improvements in HER2-positive early breast cancer with residual invasive disease, irrespective of HER2 expression of neoadjuvant chemotherapy type.

Myeloablative Orca-Q demonstrated efficacy and safety in high-risk hematologic malignancies.

GC012F/AZD0120 produced responses in high-risk, transplant-eligible multiple myeloma, as well as transplant-ineligible, newly diagnosed disease.

Acalabrutinib plus rituximab followed by brexu-cel was safe and delivered responses in previously untreated, high-risk mantle cell lymphoma.

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations

In the CARTITUDE-4 trial, 80.5% of patients with standard-risk multiple myeloma were progression-free at 2.5 years after receiving cilta-cel.

Those with metachronous NMIBC experienced poorer outcomes with BCG vs those with primary NMIBC.

A look at the top multiple myeloma abstracts set to be presented at the 2025 ASH Annual Meeting.

Silevertinib produced responses in NSCLC harboring non-classical EGFR mutations and will also be investigated in newly diagnosed glioblastoma.

The prescribing information for cosibelimab in advanced cutaneous squamous cell carcinoma was updated to include long-term data from the CK-301-101 trial.

The FDA approved durvalumab plus FLOT for the perioperative treatment of resectable gastric and gastroesophageal junction cancers.

Joshua Richter, MD, discusses the evaluation of the FcRH5 x CD3 bispecific antibody in multiple myeloma.

Subcutaneous toripalimab generated non-inferior efficacy and safety outcomes vs the IV formulation in recurrent/metastatic non squamous NSCLC.

The FDA granted fast track designation to AVZO-103 for urothelial cancer previously treated with enfortumab vedotin.

Shubham Pant, MD, MBBS, explores frontline chemotherapy decision-making in metastatic pancreatic cancer.

Sequential intracerebroventricular and intraventricular administration of CAR T-cell therapy was better tolerated in pediatric central nervous system tumors.

HER2-directed CAR T-cell therapy was safe in patients with brain/leptomeningeal metastases from HER2-positive breast cancer.

Vorasidenib plus temozolomide was safe in glioma harboring IDH1/2 mutations.

The FDA has approved neoadjuvant/adjuvant enfortumab vedotin plus pembrolizumab for cisplatin-ineligible muscle-invasive bladder cancer.

Will the FDA approve zidesamtinib for ROS1-positive advanced non–small cell lung cancer after a prior TKI?

Joshua Richter, MD, discusses the exploration of CELMoDs in the treatment of patients with multiple myeloma.